Roche says its C5 in­hibitor aced PhI­II head-to-head tri­als with As­traZeneca’s Soliris

One of the new drugs Roche is bank­ing on for a 2023 launch has cleared two Phase III tri­als, the com­pa­ny re­port­ed.

Roche’s Genen­tech test­ed croval­imab, a C5 in­hibitor, in two dif­fer­ent groups of pa­tients with the rare blood dis­or­der parox­ys­mal noc­tur­nal he­mo­glo­bin­uria and reached two con­clu­sions: First­ly, its drug works just as well as As­traZeneca’s block­buster Soliris, a cur­rent stan­dard of care, among pa­tients who have not been treat­ed with com­ple­ment in­hibitors; and sec­ond­ly, it’s safe for pa­tients to switch from cur­rent­ly ap­proved C5 in­hibitors to croval­imab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER